3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Stomach Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Head and Neck Carcinoma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Cancer Patients
1
Interventions
pembrolizumab
10
Nivolumab
9
Ipilimumab
4
avelumab
3
Neoadjuvant Therapy
3
toripalimab
2
sintilimab
2
durvalumab
2
atezolizumab
2
Specimen Handling
2
Immune Checkpoint Inhibitors
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Oxaliplatin
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Turcot syndrome
×
DEAE-Dextran
×
Clear all
NCT07403877
2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2
Not yet recruiting
114 enrolled